Repligen Corporation
HealthcareNASDAQ:RGEN · NASDAQ Global Select
-$2.74 today
Vol 1.27M · Avg 1.08M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $582.6M |
| Short-term Investments | $201.9M |
| Receivables | $151.6M |
| Inventory | $179.3M |
| Other Current | $46.0M |
| Total Current Assets | $1.2B |
| PP&E (Net) | $287.1M |
| Goodwill | $1.1B |
| Intangible Assets | $368.2M |
| Long-term Investments | $2.0M |
| Tax Assets | $1.4M |
| Other Non-current | $3.9M |
| Total Non-current Assets | $1.8B |
| Total Assets | $2.9B |
Analysis
Selected assets total $2.9B for Latest. The largest visible component is Goodwill at $1.1B, about 37.8% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $566.0M -25.3% | $757.4M +0.8% | $751.3M +43.5% | $523.5M -13.3% | $603.8M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $201.6M | $0 | $0 -100.0% | $100.3M | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $158.6M +18.2% | $134.1M +8.0% | $124.2M +6.8% | $116.2M -1.0% | $117.4M | $533.8M | $399.4M | -$1.7B |
| Inventory | $170.5M +19.2% | $143.0M -29.3% | $202.3M -15.1% | $238.3M +29.2% | $184.5M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $27.1M +31.8% | $20.6M +3.4% | $19.9M +14.4% | $17.4M -9.6% | $19.3M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $1.1B +6.7% | $1.1B -4.1% | $1.1B +11.3% | $998.1M +7.1% | $931.7M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $306.2M -8.1% | $333.1M +3.1% | $323.0M +2.3% | $315.7M +39.4% | $226.5M | $1.2B | $1.5B | $687.8M |
| Goodwill | $1.1B +8.1% | $1.0B +4.4% | $987.1M +15.4% | $855.5M -0.6% | $860.4M | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $386.1M -3.0% | $397.9M -2.2% | $407.0M +12.8% | $360.6M +6.9% | $337.3M | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $694.0K -7.3% | $749.0K -51.0% | $1.5M +82.1% | $840.0K -55.9% | $1.9M | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $4.9M +466.0% | $868.0K -32.0% | $1.3M +56.7% | $815.0K +32.5% | $615.0K | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $1.8B +2.8% | $1.8B +2.5% | $1.7B +12.2% | $1.5B +7.5% | $1.4B | -$15.3B | $14.8B | $11.3B |
| Total Assets | $2.9B +4.2% | $2.8B -0.1% | $2.8B +11.8% | $2.5B +7.3% | $2.4B | $13.3B | $11.9B | $10.6B |
| Account Payables | $30.0M -6.6% | $32.1M +64.3% | $19.6M -29.0% | $27.6M -23.9% | $36.2M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $21.6M | $0 -100.0% | $69.5M -75.6% | $284.6M +11.5% | $255.3M | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 -100.0% | $6.8M +177.1% | $2.5M -50.7% | $5.0M | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $14.6M +10.3% | $13.2M -22.4% | $17.1M -11.5% | $19.3M +31.4% | $14.7M | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $25.9M -47.4% | $49.3M +66.3% | $29.6M -37.6% | $47.5M +12.6% | $42.1M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $135.8M +7.1% | $126.8M -23.1% | $164.9M -59.2% | $404.2M +7.7% | $375.3M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $542.2M +3.2% | $525.6M +3.0% | $510.1M | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $22.5M -1.2% | $22.8M -42.1% | $39.3M +71.0% | $23.0M -31.3% | $33.5M | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $1.5M | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $15.3M -57.7% | $36.2M +43.0% | $25.4M -59.3% | $62.3M -35.8% | $97.1M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $707.7M -3.1% | $730.2M +4.1% | $701.4M +223.7% | $216.7M -7.0% | $233.0M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $843.6M -1.6% | $856.9M -1.1% | $866.3M +39.5% | $620.9M +2.1% | $608.3M | $14.7B | $3.7B | $9.6B |
| Common Stock | $563.0K +0.4% | $561.0K +0.5% | $558.0K +0.4% | $556.0K +0.5% | $553.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | $456.2M +12.0% | $407.4M -5.9% | $432.9M +9.0% | $397.3M +104.7% | $194.1M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$2.5M +95.2% | -$52.5M -38.9% | -$37.8M -9.9% | -$34.4M -103.7% | -$16.9M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $2.1B +6.8% | $2.0B +0.4% | $2.0B +2.8% | $1.9B +9.2% | $1.8B | $9.1B | $7.7B | $3.3B |
| Total Debt | $689.9M +0.5% | $686.2M -3.6% | $711.8M +68.3% | $423.0M +15.5% | $366.1M | $724.2M | $410.6M | $399.4M |
| Net Debt | $123.9M +274.3% | -$71.1M -79.9% | -$39.5M +60.7% | -$100.5M +57.7% | -$237.8M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
DaVita Inc.
NYSE:DVA
$13.40B
Globus Medical, Inc.
NYSE:GMED
$10.84B
Baxter International Inc.
NYSE:BAX
$10.77B
Masimo Corporation
NASDAQ:MASI
$9.42B
Charles River Laboratories International, Inc.
NYSE:CRL
$9.03B
Bio-Rad Laboratories, Inc.
NYSE:BIO
$7.73B
AptarGroup, Inc.
NYSE:ATR
$7.51B
Avantor, Inc.
NYSE:AVTR
$6.41B
Stevanato Group S.p.A.
NYSE:STVN
$4.66B
SEC Filings
Recent regulatory filings
No filings found.
How much cash does RGEN have?
Repligen Corporation (RGEN) reported $566.02M in cash and equivalents in fiscal 2025.
How much debt does RGEN carry?
Repligen Corporation (RGEN) reported $689.95M of total debt, with net debt of $123.93M.
Explore More
Continue the stock analysis
Jump to another research area for this company.